Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Director | February 28, 2019 | March 02, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date February 28, 2019 · Filed March 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.54 · Expires 2029-02-28 | Direct | 5,000 |
Reported balance
After 2019-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-28 · Grant · Acquired 5,000 · Balance 5,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2019), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2020 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2019), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2020 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 2, 2019 01:03 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $102.54 | $0.00 |
DisclosureSEC source: 0001177648-19-000019 · edgar.xml · derivative · entry 1 Buckley Stephen Jr. · CIK 0001571830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2019), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2020 annual meeting of stockholders. Read SEC document |
| February 28, 2018 Filed Mar 6, 2018 00:14 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $78.62 | $0.00 |
DisclosureSEC source: 0001177648-18-000009 · edgar.xml · derivative · entry 1 Buckley Stephen Jr. · CIK 0001571830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-02-28 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 00:32 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $29.02 | $0.00 |
DisclosureSEC source: 0001177648-17-000012 · edgar.xml · derivative · entry 1 Buckley Stephen Jr. · CIK 0001571830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-02-16 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 16, 2017), with the final monthly installment vesting at the 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.